Vertex Jumps On Hepatitis C Trials
Shares of Vertex Pharmaceuticals (VRTX) skyrocketed by more than 20% in pre-market action on Friday as the company announced positive results from its Hepatitis C drug trials.
24 out of the 26 patients who have recieved a combination therapy of interferon with Vertex's Hep C investigational protease inhibitor, telaprevir, did not show any evidence of viral RNA. Some patients were viral RNA free even after stopping therapy.
The details of the phase 1b study will be presented on Monday at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Shares of Vertex are currently trading at $43.28 before the morning bell.
_
Shares of Vertex Pharmaceuticals (VRTX) skyrocketed by more than 20% in pre-market action on Friday as the company announced positive results from its Hepatitis C drug trials.
24 out of the 26 patients who have recieved a combination therapy of interferon with Vertex's Hep C investigational protease inhibitor, telaprevir, did not show any evidence of viral RNA. Some patients were viral RNA free even after stopping therapy.
The details of the phase 1b study will be presented on Monday at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Shares of Vertex are currently trading at $43.28 before the morning bell.
_
posted by Nico at
9:12 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home